Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Affimed N-V stock | $6.26

Learn how to easily invest in Affimed N-V stock.

Affimed N.V is a biotechnology business based in the US. Affimed N-V shares (AFMD) are listed on the NASDAQ and all prices are listed in US Dollars. Affimed N-V employs 153 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Affimed N-V

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – AFMD – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Affimed N-V stock price (NASDAQ: AFMD)

Use our graph to track the performance of AFMD stocks over time.

Affimed N-V shares at a glance

Information last updated 2021-09-19.
Latest market close$6.26
52-week range$3.09 - $11.74
50-day moving average $6.50
200-day moving average $7.85
Wall St. target price$14.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.43

Buy Affimed N-V shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Affimed N-V stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Affimed N-V price performance over time

Historical closes compared with the close of $6.26 from 2021-09-24

1 week (2021-09-17) -2.03%
1 month (2021-08-25) -5.15%
3 months (2021-06-25) -24.03%
6 months (2021-03-26) -19.43%
1 year (2020-09-25) 87.99%
2 years (2019-09-25) 83.58%
3 years (2018-09-25) 36.09%
5 years (2016-09-23) 112.93%

Affimed N-V financials

Revenue TTM $42.6 million
Gross profit TTM $28.9 million
Return on assets TTM -12.51%
Return on equity TTM -39.9%
Profit margin -89.61%
Book value $1.26
Market capitalisation $765.1 million

TTM: trailing 12 months

Shorting Affimed N-V shares

There are currently 4.2 million Affimed N-V shares held short by investors – that's known as Affimed N-V's "short interest". This figure is 13% up from 3.8 million last month.

There are a few different ways that this level of interest in shorting Affimed N-V shares can be evaluated.

Affimed N-V's "short interest ratio" (SIR)

Affimed N-V's "short interest ratio" (SIR) is the quantity of Affimed N-V shares currently shorted divided by the average quantity of Affimed N-V shares traded daily (recently around 1.1 million). Affimed N-V's SIR currently stands at 3.81. In other words for every 100,000 Affimed N-V shares traded daily on the market, roughly 3810 shares are currently held short.

However Affimed N-V's short interest can also be evaluated against the total number of Affimed N-V shares, or, against the total number of tradable Affimed N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Affimed N-V's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Affimed N-V shares in existence, roughly 40 shares are currently held short) or 0.0364% of the tradable shares (for every 100,000 tradable Affimed N-V shares, roughly 36 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Affimed N-V.

Find out more about how you can short Affimed N-V stock.

Affimed N-V share dividends

We're not expecting Affimed N-V to pay a dividend over the next 12 months.

Affimed N-V share price volatility

Over the last 12 months, Affimed N-V's shares have ranged in value from as little as $3.085 up to $11.74. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Affimed N-V's is 2.6468. This would suggest that Affimed N-V's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Affimed N-V overview

Affimed N. V. , a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, which has completed Phase II clinical study of CD30-positive T-cell lymphoma, and hodgkin lymphoma (HL), as well as is in Phase II clinical trials for peripheral T-cell lymphoma, and transformed mycosis fungoides; that is in Phase I clinical study in combination with adoptive NK cells for CD30-postive lymphomas; and has completed Phase Ib clinical study in combination with anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed HL. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase I/IIa clinical trials for the treatment of advanced cancer patients; and AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma. The company has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc. ; Roivant Sciences Ltd.

Frequently asked questions

What percentage of Affimed N-V is owned by insiders or institutions?
Currently 2.771% of Affimed N-V shares are held by insiders and 67.147% by institutions.
How many people work for Affimed N-V?
Latest data suggests 153 work at Affimed N-V.
When does the fiscal year end for Affimed N-V?
Affimed N-V's fiscal year ends in December.
Where is Affimed N-V based?
Affimed N-V's address is: Technologiepark, Heidelberg, Germany, 69120
What is Affimed N-V's ISIN number?
Affimed N-V's international securities identification number is: NL0010872420
What is Affimed N-V's CUSIP number?
Affimed N-V's Committee on Uniform Securities Identification Procedures number is: N01045108

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site